

87-procainamide hydrochloride (CAS# 614-39-1)															
Table 1a. Sub-lethal acute poisoning (single dose): Clinical observations (time related)															
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to recovery): h
1	Villalba-Pimentel 1973	1	79M	Z	18.75	(b)	0.5	pl	59	252	(a)	(a)	0h:MS,HA,LP,V	0h:ST	
		1					2.5	pl, p	77	327			1h:C,RA	1h:AR	
		1					5.5	pl	59	251			2.5 h:P	2.5h:PD 24 h	
		1					24	pl	14	59					24
2	Atkinson 1976	2	67F	U	21.0	(c)	8	pl, p	57	242	55	202	0h:LP,HA,KF	0h:ST	
		2					13	pl	21	89	41	151	I:C	41h:HD 4 h	
		2					28	pl	9	38	33	121	45h:RM,C,LP		
3	Schwartz 1984	3	63M	U	8.0	(d)	24	sr, p	42	178	26	96	0h:LP,HA,KF		
		3											I:C	(e)	NR
		3					120		9.5	40			72h:RM,N,H		
4	Goldstein 1988	4	67F	Z	NR	(f)	7		106	450	44	162	0h:C,SZ,LP,HA,KF	0h:ST	
		4				ET	8		101	429	49	180	ET 7h: RM, HA, C	I:HD 6h	NR
		4					13		29	123	25	92			
Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]															
MW procainamide = 235.4															
MW N-acetylprocainamide (NAPA) = 271.8															
(a) NAPA.															
(b) slight angina pectoris and kidney insufficiency.															
(c) a history of 2 previous myocardial infarctions, the most recent 6 weeks before admission; therapeutic d (0.125 mg daily), furosemide (80 mg daily), and nitroglycerin as needed; repeated therapeutic overdose of procainamide daily, in 7 days.															
(d) history of mild renal insufficiency, severe ischemic cardiomyopathy, and chronic ventricular tachycardia.															
(e) treatment of deep venous thrombosis with warfarin (5 mg/day); treatment of urinary tract infection with sulfamethoxazole (80 mg twice a day) and trimethoprim (160 mg twice a day).															
(f) controlled supraventricular tachycardia.															

Table 1b. Sub-lethal acute poisoning (single dose): Clinical observations (without time information)															
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to recovery): h
1	Prendergast 1984	1	21M	U	NR	(b)		sr	31.8	135	25.8	95	MS,H	NR	NR
Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]															
MW procainamide = 235.4															
MW N-acetylprocainamide (NAPA) = 271.8															
(a) NAPA.															
(b) oral and i.v. dosage in 2 days.															
Table 2a. Lethal acute poisoning (single dose): Clinical observations (time related)															
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to death): h
no cases															
Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]															
MW procainamide = 235.4															
Table 2b. Lethal acute poisoning (single dose): Clinical observations (without time information)															
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to death): h
1	AAPCC 1988:411	1	61 NR	NR	NR				6	25					

2	AAPCC 1994:601	2	58 A	NR	NR	(b)			19	81					
3	AAPCC 1994:602	3	65 U,Z	NR	NR	(a)			13	55					
4	AAPCC 1994:603	4	66 A	NR	NR	(a) (b)			16	68					

Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]

MW procainamide = 235.4															
(a) therapeutic error.															
(b) parenteral.															

Table 3a. Post-mortem observations (time related)

Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to death): h

Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]

MW procainamide = 235.4															
-------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Table 3b. Post-mortem observations (without time information)

Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose: g	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Metabolite Blood conc.: µM	Symptoms and signs	Treatment	Time (exposure to death): h
1	Baselt 1995	1	4 cases		(a)				145	616			NR		
		2	Ad		NR				114	484			NR		

Footnotes [General Glossary (via link) lists definitions of common abbreviations (general terms, symptoms and signs, treatment)]

MW procainamide = 235.4															
(a) range 80-260 mg/l.															